<DOC>
	<DOCNO>NCT01325428</DOCNO>
	<brief_summary>The general aim study investigate efficacy safety afatinib alone combination weekly vinorelbine ( patient progress afatinib monotherapy within trial ) treatment patient HER2-overexpressing , locally advanced metastatic inflammatory breast cancer . The study include patient fail prior trastuzumab treatment .</brief_summary>
	<brief_title>Afatinib ( BIBW2992 ) HER2 ( Human Epidermal Growth Factor Receptor 2 ) -Overexpressing Inflammatory Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion criterion : 1 . Female patient &gt; =18 year proven diagnosis HER2overexpressing , histologically confirm breast cancer 2 . Locally advanced metastatic disease 3 . Must disease evaluate accord RECIST 1.1 ( Response Evaluation Criteria Solid Tumours version 1.1 ) 4 . For trastuzumab pretreated patient , must fail prior trastuzumab treatment 5 . Investigatorconfirmed diagnosis Inflammatory Breast Cancer 6 . Must biopsiable disease Exclusion criterion : 1 . Prior treatment HER2targeted small molecule antibody trastuzumab ( must give trastuzumabfailure study population ) 2 . Must receive prior vinorelbine treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>